– Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –
Barchart Research What to Expect from EWTX Earnings EWTX Generated August 5, 2026 Current Price $44.99 EPS Estimate $$-0.48 Consensus Rating Strong Buy Average Move 2.50% Edgewise Reports Tomorrow With...
— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones —
BOULDER, Colo. , July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% –
BOULDER, Colo. , June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...
— Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones —
BOULDER, Colo. , May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present...
– Announced positive long-term sevasemten data demonstrating sustained functional stabilization in Becker muscular dystrophy (Becker) up to 3.5 years of follow-up –
BOULDER, Colo. , May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...